scholarly journals The Retrospective Evaluation of Severe Hypertriglyceridemia Occurred During Therapy in Children with Acute Lymphoblastic Leukemia: Experience of Two Centers

LLM Dergi ◽  
2018 ◽  
Vol 2 (4) ◽  
pp. 84-88
Author(s):  
Melek ERDEM ◽  
Özlem TÜFEKÇİ ◽  
Tuba Hilkay KARAPINAR ◽  
Yeşim OYMAK ◽  
Birsen BAYSAL ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Retrospective Evaluation ◽  
Severe Hypertriglyceridemia

Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia

2020 ◽  
Vol 37 (6) ◽  
pp. 530-538 ◽  
Author(s):  
Christina Mayerhofer ◽  
Carsten Speckmann ◽  
Friedrich Kapp ◽  
Ulrike Teufel-Schäfer ◽  
Wolfram Kluwe ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Induction Therapy ◽  
Lymphoblastic Leukemia ◽  
Lipid Apheresis ◽  
Severe Hypertriglyceridemia

scholarly journals Venous Thromboembolism and Its Risk Factors in Children with Acute Lymphoblastic Leukemia in Israel: A Population-Based Study

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2759
Author(s):  
Shlomit Barzilai-Birenboim ◽  
Ronit Nirel ◽  
Nira Arad-Cohen ◽  
Galia Avrahami ◽  
Miri Ben Harush ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Univariate Analysis ◽  
Population Based ◽  
Population Based Study ◽  
Inherited Thrombophilia ◽  
Severe Hypertriglyceridemia

Venous thromboembolism (VTE) is a serious complication of acute lymphoblastic leukemia (ALL) therapy. The aim of this population-based study was to evaluate the rate, risk factors, and long-term sequelae of VTE in children treated for ALL. The cohort included 1191 children aged 1–19 years diagnosed with ALL between 2003–2018, prospectively enrolled in two consecutive protocols: ALL-IC BFM 2002 and AIEOP-BFM ALL 2009. VTEs occurred in 89 patients (7.5%). Long-term sequelae were uncommon. By univariate analysis, we identified four significant risk factors for VTEs: Severe hypertriglyceridemia (p = 0.005), inherited thrombophilia (p < 0.001), age >10 years (p = 0.015), and high-risk ALL group (p = 0.039). In addition, the incidence of VTE was significantly higher in patients enrolled in AIEOP-BFM ALL 2009 than in those enrolled in ALL-IC BFM 2002 (p = 0.001). Severe VTE occurred in 24 children (2%), all of whom had at least one risk factor. Elevated triglyceride levels at diagnosis did not predict hypertriglyceridemia during therapy. In a multivariate analysis of 388 children, severe hypertriglyceridemia and inherited thrombophilia were independent risk factors for VTE. Routine evaluation for these risk factors in children treated for ALL may help identify candidates for intervention.

Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia

2019 ◽  
Vol 26 (1) ◽  
pp. 193-199 ◽  
Author(s):  
Kimberly M Lau ◽  
Ila M Saunders ◽  
Aaron Goodman
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Leukemic Cells ◽  
Hypersensitivity Reactions ◽  
Specific Enzyme ◽  
First Line ◽  
Severe Hypertriglyceridemia ◽  
Adult Acute Lymphoblastic Leukemia ◽  
Long Acting ◽  
First Line Treatment

Pegaspargase, a long acting formulation of L-asparaginase, is an asparagine specific enzyme that selectively kills leukemic cells by depleting plasma asparagine. Pegaspargase is FDA approved for the first-line treatment of adult acute lymphoblastic leukemia and is a critical component of numerous multi-chemotherapeutic regimens. Pegaspargase is associated with well-described toxicities including hypersensitivity reactions, hepatotoxicity, and thrombosis. However, hypertriglyceridemia is a much rarer complication of pegaspargase and has only been described in a limited number of reports. We present a case of severe hypertriglyceridemia after a single dose of pegaspargase. The patient was re-challenged with pegaspargase and again developed hypertriglyceridemia which was complicated by pancreatitis. Here, we summarize published reports and a literature review describing the incidence of pegaspargase-induced hypertriglyceridemia in common acute lymphoblastic leukemia protocols.

Severe hypertriglyceridemia during treatment of acute lymphoblastic leukemia associated with type III hyperlipoproteinemia

2017 ◽  
Vol 64 (11) ◽  
pp. e26530 ◽  
Author(s):  
Yuji Yamada ◽  
Haruko Shima ◽  
Hironori Shibata ◽  
Tomohiro Ishii ◽  
Tomonobu Hasegawa ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Type Iii ◽  
Type Iii Hyperlipoproteinemia ◽  
Severe Hypertriglyceridemia
Sign in / Sign up

Export Citation Format

Share Document